Aarti Drugs

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE767A01016
NSEID: AARTIDRUGS
BSEID: 524348
View on NSE | View on BSE

INR

390.60

7.05 (1.84%)

BSENSE

Feb 03

BSE+NSE Vol: 2.73 lacs

Access older stock analysis version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Senores Pharma.

Innova Captab

Aarti Drugs

Guj. Themis Bio.

RPG LifeScience.

Zota Health Care

Dishman Carbogen

Advanced Enzyme

Gufic BioScience

Orchid Pharma

SPARC

Why is Aarti Drugs Ltd ?

Poor long term growth as Operating profit has grown by an annual rate -5.65% of over the last 5 years

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -7.09% returns in the last 1 year, the stock has also underperformed BSE500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Aarti Drugs for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Aarti Drugs

-7.75%

-0.18

43.23%

Sensex

8.49%

0.74

11.41%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

3.90%

EBIT Growth (5y)

-5.65%

EBIT to Interest (avg)

9.51

Debt to EBITDA (avg)

1.73

Net Debt to Equity (avg)

0.38

Sales to Capital Employed (avg)

1.45

Tax Ratio

14.75%

Dividend Payout Ratio

5.36%

Pledged Shares

Institutional Holding

12.27%

ROCE (avg)

16.64%

ROE (avg)

15.98%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.45

EV to EBIT

16.37

EV to EBITDA

13.26

EV to Capital Employed

2.04

EV to Sales

1.68

PEG Ratio

0.57

Dividend Yield

0.26%

ROCE (Latest)

12.49%

ROE (Latest)

13.56%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company

PAT(9M)

At Rs 162.05 cr has Grown at 40.16%

OPERATING PROFIT TO INTEREST(Q)

Highest at 10.95 times

DEBT-EQUITY RATIO(HY)

Lowest at 0.39 times

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Loading Valuation Snapshot...

Here's what is working for Aarti Drugs

Profit After Tax (PAT) - Latest six months

At Rs 99.19 cr has Grown at 45.33%

Year on Year (YoY)

MOJO Watch

Near term PAT trend is very positive

PAT (Rs Cr)

Operating Profit to Interest - Quarterly

Highest at 10.95 times

in the last five quarters

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Debt-Equity Ratio - Half Yearly

Lowest at 0.39 times

in the last five half yearly periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio